Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Dexmedetomidine for Vitreoretinal Procedures
NCT03251222Phase 4Unknown
- Sponsor
- University Medical Centre Ljubljana
- Start
- Jan 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in vitreoretinal disease (VRD) comparing Dexmedetomidine group with Placebo Concentrate (2 arms). Primary endpoint: Remifentanil consumption. Status: unknown.
02
Drugs
dexmedetomidine
03
Conditions
vitreoretinal disease (VRD)
Beyond the preview
Go deeper on NCT03251222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03251222.